NMTR News and Press, 9 Meters Biopharma Inc. From 06/04/21

Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories N.V. (CLB) +...

RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will present at the Jefferies Virtual Healthcare Conference being hel...

Larazotide, a drug in development from 9 Meters Biopharma (NMTR) to treat both celiac disease in adults and a rare complication from COVID-19 in children, may have broader applications, according to Truist.Yesterday, 9 Meters highlighted a case report of an infant with a rare and serious comp...

Larazotide, in development by 9 Meters Biopharma (NMTR), led to a significant drop in inflammatory mediators in an infant with multisystem inflammatory syndrome in children (MIS-C).MIS-C is a serious, rare complication following COVID-19 infection with symptoms that include persistent fe...

- Larazotide supplied to study authors under an FDA-approved Expanded Access Program - - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing proof-of-concept support for larazotide's mechanism of action - RALEIGH, NC / ACCESSWIRE /...

This version of the release contains a corrected hyperlink. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will present...

RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will present a corporate update at Oppenheimer's Rare & Orphan Disease Su...

RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the United States Adopted Names (USAN) Council has officially designated the Company's long-actin...

- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 following FDA guidance - Announced a collaboration with the Celiac Disease Foundation (C...

Scienjoy Holding Corporation SJ +29% on launching Non-Fungible Tokens on its platforms.MICT (MICT) +17%.Ocugen (OCGN) +15%.BrainsWay BWAY +14% on FDA clearance for Deep TMS protocol.China Recycling Energy (CREG) +13%.Axsome Therapeutics AXSM +12% on FDA acceptanc...